136 related articles for article (PubMed ID: 31033435)
1. Tumor suppressor SMARCB1 suppresses super-enhancers to govern hESC lineage determination.
Langer LF; Ward JM; Archer TK
Elife; 2019 Apr; 8():. PubMed ID: 31033435
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MYC by the SMARCB1 tumor suppressor.
Weissmiller AM; Wang J; Lorey SL; Howard GC; Martinez E; Liu Q; Tansey WP
Nat Commun; 2019 May; 10(1):2014. PubMed ID: 31043611
[TBL] [Abstract][Full Text] [Related]
3. Super-Enhancer Dysregulation in Rhabdoid Tumor Cells Is Regulated by the SWI/SNF ATPase BRG1.
Jones CA; Wang J; Evans JR; Sisk HR; Womack CB; Liu Q; Tansey WP; Weissmiller AM
Cancers (Basel); 2024 Feb; 16(5):. PubMed ID: 38473277
[TBL] [Abstract][Full Text] [Related]
4. GRHL3 binding and enhancers rearrange as epidermal keratinocytes transition between functional states.
Klein RH; Lin Z; Hopkin AS; Gordon W; Tsoi LC; Liang Y; Gudjonsson JE; Andersen B
PLoS Genet; 2017 Apr; 13(4):e1006745. PubMed ID: 28445475
[TBL] [Abstract][Full Text] [Related]
5. Dynamic network-guided CRISPRi screen identifies CTCF-loop-constrained nonlinear enhancer gene regulatory activity during cell state transitions.
Luo R; Yan J; Oh JW; Xi W; Shigaki D; Wong W; Cho HS; Murphy D; Cutler R; Rosen BP; Pulecio J; Yang D; Glenn RA; Chen T; Li QV; Vierbuchen T; Sidoli S; Apostolou E; Huangfu D; Beer MA
Nat Genet; 2023 Aug; 55(8):1336-1346. PubMed ID: 37488417
[TBL] [Abstract][Full Text] [Related]
6. SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability.
Parisian AD; Koga T; Miki S; Johann PD; Kool M; Crawford JR; Furnari FB
Genes Dev; 2020 Oct; 34(19-20):1316-1329. PubMed ID: 32912900
[TBL] [Abstract][Full Text] [Related]
7. An organoid biobank for childhood kidney cancers that captures disease and tissue heterogeneity.
Calandrini C; Schutgens F; Oka R; Margaritis T; Candelli T; Mathijsen L; Ammerlaan C; van Ineveld RL; Derakhshan S; de Haan S; Dolman E; Lijnzaad P; Custers L; Begthel H; Kerstens HHD; Visser LL; Rookmaaker M; Verhaar M; Tytgat GAM; Kemmeren P; de Krijger RR; Al-Saadi R; Pritchard-Jones K; Kool M; Rios AC; van den Heuvel-Eibrink MM; Molenaar JJ; van Boxtel R; Holstege FCP; Clevers H; Drost J
Nat Commun; 2020 Mar; 11(1):1310. PubMed ID: 32161258
[TBL] [Abstract][Full Text] [Related]
8. Single-cell RNA sequencing reveals a heterogeneous response to Glucocorticoids in breast cancer cells.
Hoffman JA; Papas BN; Trotter KW; Archer TK
Commun Biol; 2020 Mar; 3(1):126. PubMed ID: 32170217
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibition creates a chromatin landscape favorable to RNA Pol II processivity.
Kinyamu HK; Bennett BD; Bushel PR; Archer TK
J Biol Chem; 2020 Jan; 295(5):1271-1287. PubMed ID: 31806706
[TBL] [Abstract][Full Text] [Related]
10. Enhancer switching in cell lineage priming is linked to eRNA, Brg1's AT-hook, and SWI/SNF recruitment.
Saha D; Animireddy S; Lee J; Thommen A; Murvin MM; Lu Y; Calabrese JM; Bartholomew B
Mol Cell; 2024 May; 84(10):1855-1869.e5. PubMed ID: 38593804
[TBL] [Abstract][Full Text] [Related]
11. Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF.
Radko-Juettner S; Yue H; Myers JA; Carter RD; Robertson AN; Mittal P; Zhu Z; Hansen BS; Donovan KA; Hunkeler M; Rosikiewicz W; Wu Z; McReynolds MG; Roy Burman SS; Schmoker AM; Mageed N; Brown SA; Mobley RJ; Partridge JF; Stewart EA; Pruett-Miller SM; Nabet B; Peng J; Gray NS; Fischer ES; Roberts CWM
Nature; 2024 Apr; 628(8007):442-449. PubMed ID: 38538798
[TBL] [Abstract][Full Text] [Related]
12. BRG1 establishes the neuroectodermal chromatin landscape to restrict dorsal cell fates.
Hoffman JA; Muse GW; Langer LF; Patterson AI; Gandara I; Ward JM; Archer TK
Sci Adv; 2024 Mar; 10(9):eadj5107. PubMed ID: 38427725
[TBL] [Abstract][Full Text] [Related]
13. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.
Amara CS; Kami Reddy KR; Yuntao Y; Chan YS; Piyarathna DWB; Dobrolecki LE; Shih DJH; Shi Z; Xu J; Huang S; Ellis MJ; Apolo AB; Ballester LY; Gao J; Hansel DE; Lotan Y; Hodges HC; Lerner SP; Creighton CJ; Sreekumar A; Zheng WJ; Msaouel P; Kavuri SM; Putluri N
Nat Commun; 2024 Feb; 15(1):1373. PubMed ID: 38355560
[TBL] [Abstract][Full Text] [Related]
14. SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors.
Liu NQ; Paassen I; Custers L; Zeller P; Teunissen H; Ayyildiz D; He J; Buhl JL; Hoving EW; van Oudenaarden A; de Wit E; Drost J
Nat Commun; 2023 Dec; 14(1):7762. PubMed ID: 38040699
[TBL] [Abstract][Full Text] [Related]
15. HIV-1 Vpu protein forms stable oligomers in aqueous solution via its transmembrane domain self-association.
Majeed S; Dang L; Islam MM; Ishola O; Borbat PP; Ludtke SJ; Georgieva ER
Sci Rep; 2023 Sep; 13(1):14691. PubMed ID: 37673923
[TBL] [Abstract][Full Text] [Related]
16. Superenhancers as master gene regulators and novel therapeutic targets in brain tumors.
Zhuang HH; Qu Q; Teng XQ; Dai YH; Qu J
Exp Mol Med; 2023 Feb; 55(2):290-303. PubMed ID: 36720920
[TBL] [Abstract][Full Text] [Related]
17. SMARCB1-Deficient Cancers: Novel Molecular Insights and Therapeutic Vulnerabilities.
Cooper GW; Hong AL
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35892904
[TBL] [Abstract][Full Text] [Related]
18. ATAC-seq Optimization for Cancer Epigenetics Research.
Cooper M; Ray A; Bhattacharya A; Dhasarathy A; Takaku M
J Vis Exp; 2022 Jun; (184):. PubMed ID: 35848835
[TBL] [Abstract][Full Text] [Related]
19. Acute depletion of the ARID1A subunit of SWI/SNF complexes reveals distinct pathways for activation and repression of transcription.
Blümli S; Wiechens N; Wu MY; Singh V; Gierlinski M; Schweikert G; Gilbert N; Naughton C; Sundaramoorthy R; Varghese J; Gourlay R; Soares R; Clark D; Owen-Hughes T
Cell Rep; 2021 Nov; 37(5):109943. PubMed ID: 34731603
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
